secwatch.observer — SEC 8-K summary
======================================

Issuer:     CODEXIS, INC. (CDXS)
CIK:        0001200375
Form:       8-K
Filed at:   2022-08-04T23:59:59+00:00
Accession:  0001200375-22-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Codexis Q2 revenue up 51% to $38.4M; CEO Nicols to retire; Dilly appointed
--------------------------------------------------------------------------

- Product revenue surged 135% YoY to $34.6M, driven by Pfizer PAXLOVID enzyme sales.
- Net loss narrowed to $2.6M ($0.04 per share) from $4.3M a year ago.
- CEO John Nicols retiring for family reasons; Dr. Stephen Dilly to become CEO on Aug 9, 2022.
- Reaffirmed FY2022 guidance: total revenue $135-141M, product revenue $112-118M incl. ~$75M from Pfizer.
- Cash and equivalents $90.1M; expects to fund operations through end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000030/0001200375-22-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1200375/000120037522000030/cdxs-20220804.htm
  HTML page:      https://secwatch.observer/filing/0001200375-22-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer